Distal gastric bypass
ProcedureDistal gastric bypass, revisonal surgery after failed RYGB
NCT Number: NCT04894838
This study is designed as a prospective multicenter randomized controlled clinical trial comparing two surgical techniques of distal gastric bypass (DGB) in revisional surgery following failed Roux-en-Y gastric bypass. Patients will be randomly allocated 1:1 to A) DGB with lengthening of the BPL (DGB type I) or B) DGB with extended AL (DGB type II). Randomisation is stratified for participating center. The study will be performed in a clinical and out-patient setting with regular visits at 1.5, 3, 6, 12, 18, 24 and 36 months post intervention. The study will be set up as a multicenter study with bariatric centers: St. Antonius hospital, Groene Hart hospital, OLVG, Rijnstate hospital, Elisabeth Twee-steden Hospital, Bravis hospital, Medisch Centrum Leeuwarden, Catharina Hospital.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Rijnstate Hospital, Arnhem, Gelderland, Netherlands
Rationale: Up to 35% of morbidly obese patients undergoing Roux-en-Y gastric bypass (RYGB) fail to lose sufficient weight or regain excessive weight after initial weight loss. Currently, there is no standardized approach to revisional surgery after failed RYGB. Distalisation of the RYGB limbs (DGB), with shortening of the common channel and extending either the alimentary limb (AL) or biliopancreatic limb (BPL), can be performed as revisional surgery to induce additional weight loss. To date, there is no general consensus as to optimal surgical technique or limb lengths to be used in distalisation of RYGB in both literature as well as clinical practice.
Objective: The aim of this study is to investigate the effect of two distalisation techniques of a gastric bypass in revisional surgery with standardised limb lengths in total weight loss (TWL) and the need for treatment for protein calorie malnutrition (PCM). In this randomised controlled trial DGB with lengthening of the BPL (DGB type I) will be compared to DGB with extended AL (DGB type II) in order to conclude which surgical technique is the optimal therapeutic strategy as revision surgery following Roux-en-Y gastric bypass.
Study design: A multicentre randomised controlled trial.
Study population: Morbidly obese patients with insufficient weight loss or weight regain following primary RYGB, who are eligible for distalisation surgery.
Intervention: A total of 150 participants will be randomised over two treatment groups: group A will undergo DGB type I and group B will undergo DGB type II.
Main study endpoints: Primary endpoints: %TWL 1 year after treatment and need for treatment of PCM. Secondary endpoints: weight loss, co-morbidity remission, PCM grading (debilitating defecation patterns, temporary total parenteral nutrition treatment, revision, mortality), morbidity, nutritional deficiencies, quality of life and patient satisfaction.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Distal gastric bypass, revisonal surgery after failed RYGB
Time frame: 1 year post-operative
Percentage total weight loss (%TWL) 1 year after treatment
Time frame: 1 year postoperative
>6 times/day defecation patterns with diarrhea, assessed by fecal score questionnaire
Time frame: Up to 3 year follow up
Patient weight in kilograms is collected preoperative up to 3 years follow-up to determine weight loss.
Time frame: 3, 6, 12, 18, 24, 36 month follow up
Weight loss in kilograms at a follow-up time point divided by weight in kilograms measured at DGB
Time frame: 3, 12 and 36 months postoperative
Faecal score questionnaire to measure defecation frequencey and consistency
Time frame: up to 3 year follow up
Information is collected about each patient who has undergone DGB to ascertain debilitating defecation patterns (grade I), requirement of f participants requiring temporary total parenteral nutrition (grade II, revision surgery (grade III), and mortality (grade IV) after DGB.
Time frame: uo to 3 year follow up
Information is collecting regarding the occurrence of one or more defined adverse events following DGB. Defined adverse events collected are: unplanned readmission to hospital, unplanned admission to the intensive care unit, unplanned return to the operating theatre, prolonged length of stay in hospital, and death. The reason for any of the events is also collected. If death occurs, the cause of death is collected to determine the likelihood of the death being caused by the DGB.
Time frame: 3, 12 and 36 months postoperative
BODY-Q questionnaire
Time frame: 3, 12 and 36 months postoperative
Fecal incontinence quality of life scale FIQL questionnaires
Time frame: 1 and 3 year postoperative
Self-designed 5-point scale measuring instrument for patient satisfaction
Time frame: 3, 12 and 36 months postoperative
Three factor earing questionnaire TFEQ R21
Contact information is provided by the study sponsor or research team.
Luna Tolenaars, MD
CONTACT
M.J. Wiezer, PhD, MD
CONTACT
St. Antonius Hospital
Other
Acronym: DISCOURSE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05725967
Abdominal Obesity, Abdominal Pain
Boston, Massachusetts, United States
View Trial DetailsNCT06287307
Body Weight, Body Weight Changes
View Trial DetailsNCT04782648
Bariatric Surgery Candidate, Body Weight
Recklinghausen, North Rhine-Westphalia, Germany
View Trial DetailsNCT06200961
Body Weight, Digestive System Diseases
Boston, Massachusetts, United States
View Trial Details